December 3, 2018 – People may think that an automated artificial intelligence (AI) system for pathology that achieves a performance of 90 percent outperforms pathologists. However, pathologists are using microscopes for a task that includes complex computations –...
Westminster, CO — November 13, 2018 — CIOReview has named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review. “The ease of leveraging Flagship’s powerful...
Westminster, CO – November 8, 2018 — Flagship’s precision medicine solutions and cTA® platform are featured in a recent GEN article, Precision Biomarkers and Medicines Go Global, summarizing highlights from the recent Clinical Biomarkers and World CDx conference in...
November 4, 2018 – Flagship Biosciences will present its artificial intelligence (AI) driven pathology solutions at the Digital Pathology Association’s 2018 Pathology Visions conference, November 4 – 6, 2018, in San Diego, CA.
October 31, 2018 – Flagship Biosciences is honored to be named by Industry Era Magazine as one of the 10 Best Technology Solution Providers of 2018. The Industry Era Magazine article, Connecting Patients with Life-saving Drugs, notes Flagship’s ground-breaking...
October 30, 2018 – The true barrier for pathology AI is the business model, not the technology. To get pathology AI into the clinical laboratories, payers need to provide a value-based model that creates a viable business case. We estimate the U.S. anatomic pathology...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
PUBLICATIONS
Key Concepts: Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study was published in the Archives of Pathology & Laboratory...
Key Concepts: While the current diagnostic strategies for PD-L1 checkpoint inhibitors identify some responders well, the majority of patients still need diagnostic approaches that better predict response. PD-L1 IHC remains a valuable tool for predicting patient...
Key takeaways Understanding the frequency and nature of immune cell clustering is useful in determining patient responses to immunomodulating therapies Flagship’s unique spatial biology services generated a validated computational pathology score that characterized...
EVENTS
View our Webcast Recording on TissueInsight®: Realizing the Clinical Diagnostic Potential of Digital Pathology. This recorded webcast will benefit pathologists and oncologists, attending physicians, image analysts, and those interested in digital pathology. Attendees...
SITC 2021 Annual Meeting:Flagship plans to present a poster at the Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting, which is taking place both virtually and in person November 10-14, 2021 at the Walter E. Washington Convention Center in...
Recently Flagship hosted a webcast on Tissue-Based CDx Development and Image Analysis in a Regulated space. Our discussion stems from the fact that the United States Food and Drug Administration (FDA) requires comprehensive analytical validation and clinical...